Shin Nippon Biomedical Laboratories Ltd (FRA:YB3) Stock Price, Trades & News

Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.

Financial Strength

3/10

Name	Current	Vs Industry
Cash-To-Debt	0.45
Equity-to-Asset	0.41
Debt-to-Equity	0.96
Debt-to-EBITDA	4.14
Interest Coverage	9.05
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.35	Distress Grey Safe
Beneish M-Score	-2.58	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	9
	3-Year EBITDA Growth Rate	1.7
	3-Year EPS without NRI Growth Rate	-12.3
	3-Year Book Growth Rate	18
	Future 3-5Y Total Revenue Growth Rate Estimate	10.98

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	86.72
	9-Day RSI	76.06
	14-Day RSI	63.52
	3-1 Month Momentum %	-25.32
	6-1 Month Momentum %	-36.9
	12-1 Month Momentum %	-28.92

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.09
	Quick Ratio	0.71
	Cash Ratio	0.47
	Days Inventory	307.03
	Days Sales Outstanding	69.29
	Days Payable	12.38

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	4.23
	Dividend Payout Ratio	0.43
	Forward Dividend Yield %	4.2
	5-Year Yield-on-Cost %	27.56
	Shareholder Yield %	-5.32

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	49.93
	Operating Margin %	8.16
	Net Margin %	14.04
	EBITDA Margin %	30.66
	FCF Margin %	8.88
	OCF Margin %	24.72
	ROE %	10.9
	ROA %	4.65
	ROIC %	2.06
	3-Year ROIIC %	-4.64
	ROC (Joel Greenblatt) %	16.22
	ROCE %	9.9
	Years of Profitability over Past 10-Year	8
	Moat Score	4
	Tariff Resilience Score	6

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	10.99
	Forward PE Ratio	12.4
	PE Ratio without NRI	10.35
	Shiller PE Ratio	14.7
	PEG Ratio	1.31
	PS Ratio	1.54
	PB Ratio	1.16
	Price-to-Tangible-Book	1.23
	Price-to-Free-Cash-Flow	16.77
	Price-to-Operating-Cash-Flow	6.02
	EV-to-EBIT	11.22
	EV-to-EBITDA	7.36
	EV-to-Revenue	2.25
	EV-to-FCF	24.49
	Price-to-GF-Value	0.69
	Price-to-Projected-FCF	1.35
	Price-to-Median-PS-Value	0.79
	Price-to-Graham-Number	0.76
	Earnings Yield (Greenblatt) %	8.92
	FCF Yield %	5.95
	Forward Rate of Return (Yacktman) %	7.77

Financials

Annual Quarterly TTM

FRA:YB3's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Shin Nippon Biomedical Laboratories Ltd Executives

Details

GF Value™: €9.41

FRA:YB3

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with YB3. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	183.604
	EPS (TTM) (€)	0.609
	Beta	0.5154
	3-Year Sharpe Ratio	-0.55
	3-Year Sortino Ratio	-0.83
	Volatility %	45.94
	14-Day RSI	63.52
	14-Day ATR (€)	0.083724
	20-Day SMA (€)	5.9825
	12-1 Month Momentum %	-28.92
	52-Week Range (€)	5.7 - 10.9
	Shares Outstanding (Mil)	41.63

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Shin Nippon Biomedical Laboratories Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Shin Nippon Biomedical Laboratories Ltd Stock Events

Financials Calendars

Event	Date	Price (€)
JPY 20.000000 Cash Dividend	2026-09-29	In 83 days
JPY 30.000000 Cash Dividend	2026-03-30	7.75 (+0.00%)
JPY 20.000000 Cash Dividend	2025-09-29	9.85 (+0.00%)
JPY 30.000000 Cash Dividend	2025-03-28	9.35 (+0.00%)
JPY 20.000000 Cash Dividend	2024-09-27	7.40 (+0.00%)
2:1 Stock Split	2005-09-27	11.79 (+0.00%)

Show

Entries

Shin Nippon Biomedical Laboratories Ltd Frequently Asked Questions

What is Shin Nippon Biomedical Laboratories Ltd(FRA:YB3)'s stock price today?

The current price of FRA:YB3 is €6.45. The 52 week high of FRA:YB3 is €10.90 and 52 week low is €5.70.

When is next earnings date of Shin Nippon Biomedical Laboratories Ltd(FRA:YB3)?

The next earnings date of Shin Nippon Biomedical Laboratories Ltd(FRA:YB3) is .

Does Shin Nippon Biomedical Laboratories Ltd(FRA:YB3) pay dividends? If so, how much?

The Dividend Yield % of Shin Nippon Biomedical Laboratories Ltd(FRA:YB3) is 4.23% (As of Today), Highest Dividend Payout Ratio of Shin Nippon Biomedical Laboratories Ltd(FRA:YB3) was 0.43. The lowest was 0.06. And the median was 0.24. The Forward Dividend Yield % of Shin Nippon Biomedical Laboratories Ltd(FRA:YB3) is 4.2%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting	2026-06-04
	Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache	2025-11-05
	Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting	2025-06-19
	Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine	2025-04-30
	Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura	2024-10-30
	Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs	2024-10-08
	Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting	2024-06-13
	Advantech Launches UTK-7521: The Latest ADA-Compliant Self-Service Kiosks	2021-10-26
	Advantech to Exhibit State-of-the-Art Healthcare Products and Solutions at HIMSS21	2021-08-03
	Advantech Introduces New AIM-75S Industrial Tablet	2021-04-29

10/Page

Articles on Shin Nippon Biomedical Laboratories Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.